Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for allegedly misleading investors regarding its revenue practices and product shipments [1][3]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Lawsuit Details - The lawsuit claims that Zynex shipped products, including electrodes, beyond actual demand, allowing the company to inflate its revenue [3]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, which could lead to adverse consequences such as removal from insurer networks and federal penalties [3]. Investor Information - Investors who purchased Zynex securities during the class period (March 13, 2023, to March 11, 2025) have until May 19, 2025, to seek appointment as lead plaintiff [2].

Core Viewpoint - A class-action lawsuit has been filed against Zynex, Inc. alleging that the company misled investors by inflating revenue through excessive and unnecessary shipments of medical supplies to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Tuncel v. Zynex, Inc., seeks to represent individuals and entities who purchased Zynex securities between March 13, 2023, and March 11, 2025, with a lead plaintiff deadline of May 19, 2025 [2][3]. - The complaint alleges that Zynex engaged in a scheme to inflate reported revenue by sending more products than medically necessary, which drew scrutiny from insurers like Tricare [3][4]. - Following a report in the medical journal STAT detailing Zynex's alleged oversupplying scheme, the company's stock price fell by over 5% [4]. Group 2: Financial Impact - Zynex disclosed a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [5]. - The announcement of the revenue shortfall led to a sharp decline in Zynex's share price, which plummeted by more than 51% [5]. - In Q1 2025, Zynex reported net revenue of $26.6 million, down from $46.5 million in the same period of 2024, with a gross profit margin contracting to 69% from 80% [6]. Group 3: Future Outlook - Zynex has issued a muted revenue guidance of $27 million for Q2 2025 and anticipates an earnings per share (EPS) loss of $0.20, withholding full-year financial guidance due to uncertainty with Tricare [8]. - The CEO of Zynex acknowledged the impact of the Tricare payment suspension on revenue and indicated that the company is initiating a restructuring effort [7].

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for allegedly misleading investors regarding its revenue practices and product shipments during the class period from March 13, 2023, to March 11, 2025 [1][3] Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2] Allegations in the Lawsuit - The lawsuit claims that Zynex shipped products, including electrodes, in excess of demand, which allowed the company to inflate its revenue [3] - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare [3] - The lawsuit suggests that Zynex is likely to face adverse consequences, such as removal from insurer networks and potential penalties from the federal government [3] Investor Information - Investors who purchased Zynex securities during the class period have until May 19, 2025, to seek appointment as a lead plaintiff representative of the class [2][4]